A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Conditions: Plaque Psoriasis Interventions: Drug: JNJ-77242113; Drug: JNJ-77242113 Matching Placebo; Drug: Deucravacitinib; Drug: Deucravacitinib Matching Placebo Sponsors: Janssen Research& Development, LLC Not yet recruiting

https://clinicaltrials.gov/study/NCT06220604

Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials

More News: Psoriasis | Research | Study